| Names | |
|---|---|
| Preferred IUPAC name
(1S,9S)-9-{[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.168.764 |
| KEGG | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C22H31N3O5 | |
| Molar mass | 417.506 g·mol−1 |
| log P | 2.212 |
| Acidity (pKa) | 2.285 |
| Basicity (pKb) | 11.712 |
| Pharmacology | |
| C09AA08 (WHO) | |
| Oral | |
| Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Cilazapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure.
It was patented in 1982 and approved for medical use in 1990.
Of the eight possible stereoisomers, only the all-(S)-form is medically viable.[citation needed]
It is branded as Dynorm, Inhibace, Vascace and many other names in various countries. None of these are available in the United States as of May 2010.